UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
                                  _____________

                                    Form 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 26, 2006


                              OCEAN BIO-CHEM, INC.
               (Exact name of registrant as specified in charter)

        Florida                        0-11102                   59-1564329
(State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
of Incorporation)                                            Identification No.)

               4041 S.W. 47 Avenue, Fort Lauderdale, Florida 33314
                (Address of principal executive office Zip Code)

                                 (954) 587-6280
               Registrant's telephone number, including area code:

                                 Not Applicable
          (Former name or former address, if changes since last report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

     [ ] Written  communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     [ ] Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     [ ]  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events

     On  December  26,  2006 four  executives  and two  non-executives  of Ocean
Bio-Chem, Inc. (the "Company") each entered into written sales plans pursuant to
the guidance specified by Rule 10b5-1 under the Securities  Exchange Act of 1934
to sell an aggregate of 143,000 shares.  The executives are:

         Peter G. Dornau        President and CEO
         Edward Anchel          Vice President and CFO
         Jeffrey J. Tieger      Vice President
         Gregor M. Dornau       Vice President

     Each plan has been approved  pursuant to the terms of the Company's insider
trading policy and is part of the individual's  long-term  strategy to diversify
assets and  provides  for the sale of shares of common  stock of the  Company in
connection with exercises of vested stock options.  Other Company executives may
from time to time adopt 10b5-1 plans.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                               Ocean Bio-Chem, Inc.


December 29, 2006                              /s/ Edward Anchel
                                               ---------------------------------
                                               Edward Anchel
                                               Vice President - Finance and
                                               Chief Financial Officer